AEON Biopharma(AEON) - 2025 Q2 - Quarterly Results
AEON Biopharma(US:AEON)2025-08-12 20:06– Cash runway expected to support operations through FDA meeting and regulatory feedback – IRVINE, Calif., August 12, 2025 – AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a biopharmaceutical company seeking an accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOXÒ (onabotulinumtoxinA) biosimilar, announced its financial results for the second quarter ended June 30, 2025, and provided a business update. "We have made strong progress this quarter tow ...